Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of SSS55 in Healthy Subjects
NCT07058779Phase 1Recruiting
- Sponsor
- 3SBio
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SSS55 in complement-mediated disease (5 arms), sponsored by 3SBio. Primary endpoint: Safety and Tolerability of SSS55 injection at 22 days. Started Aug 2025; status: recruiting.
02
Drugs
SSS55
03
Conditions
complement-mediated disease
Beyond the preview
Go deeper on NCT07058779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07058779.